Action 8: Support and fund clinical and implementation research to inform development and approval as well as use of paediatric formulations included in the PADO list.
Action 9: Only fund the procurement of drugs and formulations recommended by WHO that are included in the Optimal Formulary.
Action 21: Provide funding to support actions required for quickly introducing and scale-up new, optimal paediatric formulations.
Action 35. Provide high level political leadership and advocacy at global, country and regional levels to scale up access to paediatric HIV medications for children; production of high quality data to support implementation; and Country level support to roll out.
Action 36. Continue to convene and coordinate stakeholders at a high level, including the pharmaceutical industry, FBO and civil society service providers, national governments and multilateral partners, and partners in the Start Free, Stay Free, AIDS Free Framework.
2. (individual commitment) PEPFAR committed to work with countries on a system of shared data and rotating locations for implementation studies; to develop a proposal for further expediting the regulatory approval process; and to fund the procurement of only optimal paediatric ARVs.
UNAIDS: The global AIDS update report was published and launched in July 2018 with full tables in the back on the 2017 data. UNAIDS is working with countries on setting pediatric treatment targets within NSPs. The Free to Shine Campaign was launched by the Organization of African First Ladies Against HIV/AIDS (OAFLA) and the African Union on the sidelines of the 30th Ordinary Session of the African Union in Addis Ababa, Ethiopia (January 29). UNAIDS, WHO, Abbott, EGPAF, United Nations Children's Fund, UNDP and AIDS Accountability International, are partners in supporting the Campaign. UNAIDS has also instructed their country offices to support the in-country offices of the First the Lady to establish teams that will plan national activities and rapidly move the Free to Shine Campaign forward. http://www.unaids.org/en/resources/presscentre/featurestories/2018/february/20180106_OAFLA.
The annual 3 Frees report, with 2017 data, is expected for Q3 or Q4.
The 2019 addition of the 3 Free's report will be realist in June 2019, including with the new 2018 PMTCT/PEDS data.
PEPFAR included pediatric treatment targets in all 2018, 2019, and 2020 COPs.
PEPFAR has been in touch with ViiV and Merck & Co., Inc., about their commitments to make pediatric drugs available to LMIC. The companies confirmed their intention to provide them at access pricing until generics were available, and potentially beyond.
On February 9, 2018, PEPFAR convened over fifty technical experts in Washington, D.C. to address challenges in pediatric HIV case finding, and specifically identification of pre-adolescent children with HIV before they present to facilities with illness. Specifically, the meeting focused on finding younger asymptomatic children living with HIV (<10-12 years old) outside the usual facility-based testing (PITC) and routine PMTCT programs with special interest in using OVC, faith-based, school, and other community platforms. This remains a significant issue for all implementing partners. By the end of the meeting the group developed recommendations for: Effective strategies that can be widely adopted, perhaps with adaptation to context; Strategies that show promise in pilot or small-scale, which should be further evaluated and/or scaled up; and Creative, novel ideas that can be piloted and tested.
Notes: George Siberry led and moderated the discussion. Ambassador Birx provided opening remarks. Others in attendance were representatives from CMMB, Elizabeth Glaser Pediatric AIDS Foundation, ELMA, FHI360, ICAP, Jhpiego, John Snow, Inc., Mothers2Mothers, Management Sciences for Health, Save the Children, UNICEF, University Research Co., LLC (URC) & Center for Human Services (CHS), ViiV Positive Action, WCC-EAA, World Education Inc., World Health Organziation, and World Vision International.
On March 29, 2018, PEPFAR convened diagnostics companies, donors, and select implementing partners for a one-day Consultation meeting in New York City on shared issues related to pediatric treatment such as strategies to improve access to HIV (and TB) diagnostics for infants and children in lower middle income countries (LMICs). This meeting served as a follow-on meeting to the November 2017 High-Level Dialogue on Scaling-Up Early Diagnosis and Treatment of Children and Adolescents. The meeting ended up with concrete action items for diagnostic manufacturers to address to ensure cost efficient and uninterrupted diagnosis services for Children and Adolescents.
Notes: Ambassador Birx provided opening remarks and participated in side meeting discussions with key attendees. The meeting was attended by individuals from Abbott/Alere, Becton Dickinson, CDC – International Laboratory Branch, Cepheid, Clinton Health Access Initiative, DRW, EGPAF, ELMA, Hologic, Holy See, Orasure, Roche, Columbia University, UNAIDS, UNICEF, UNITAID, WCC-EAA, World Health Organization, and the U.S. Food and Drug Administration.
PEPFAR has developed a website that makes program data available for review and analysis: https://data.pepfar.net/ PEPFAR is developing a mechanism for addressing requests from external stakeholders and partners for more detailed program data to use in important analyses. PEPFAR has not yet developed sites for implementation studies.
PEPFAR and FDA have been working on mechanisms that would enable making FDA review documents available to WHO and/or national drug regulatory authorities for tentatively approved products to facilitate more timely regulatory approval of those products for use in PEPFAR-supported HIV programs.
PEPFAR has also been working with WHO in advance of the upcoming WHO Guidelines meeting to advance optimal ARV regimens for children.
See also action 9.
12. Discourage and refrain from funding national evaluation studies that would be duplicative of studies done for WHO PQ listing or SRA approval.
13. Fund impactful technologies and interventions quickly.
14. Support in a transparent manner the procurement of commodities and operational costs to maintain and further scale-up POC EID, as well as viral load testing for infants, children, and pregnant and breastfeeding women, as an integral part of optimized and integrated national laboratory networks and in accordance with national EID and VL plans and targets.
15. Support the development of a competitive, healthy, and sustainable market for POC and laboratory technologies.
16. Continue to support WHO PQ to shorten timelines for dossier review and minimize time to national registration.
PEPFAR ensures that its funds are not used to repeat in each country evaluations of diagnostics or drugs that have already undergone appropriate evaluation for WHO PQ and/or other SRA approval.
PEPFAR has convened discussions with OraSure, WHO and other experts to develop a plan for evaluation of home-based oral fluid testing of children as a novel strategy to increase case identification of children. PEPFAR funding to CRS, through CDC, will support this evaluation and protocol development is underway. CDC has awarded PEPFAR funds to CRS to support this work, and this work is underway (April 2020).
As part of the PEPFAR/CDC award, CRS will also promote other effective and novel strategies to identify children through faith based and other community based platforms in Uganda, Zambia, Nigeria and Tanzania.
As part of a broader Faith Based Initiative, additional resources will be provided to faith-based organizations to promote case finding and better treatment outcomes for children through faith-based platforms in PEPFAR supported countries.
PEPFAR made clear in its COP19 guidance its support for use of POC (1) for EID where 2-month testing rates and rates for linkage to ART for infected infants are not on track to reach 90-95%and (2) for VL in PBF to help ensure that women maintain virologic suppression through pregnancy and breastfeeding. PEPFAR reinforced throughout the COP19 development process the importance of optimizing use of POC platforms for these purposes where performance gaps in EID persisted or could not be met by conventional laboratory platforms.
In COP 20 guidance, PEPFAR stated support of POC VL for unsuppressed PLHIV including children and adolescents.
Ongoing efforts to map and optimize VL machines/equipment.
PEPFAR continues to communicate with global partners and industry to promote development and uptake of laboratory technologies essential for diagnosis and management of HIV in children.
Apart from support for POC for EID and VL mentioned above, PEPFAR continues to work with manufacturers and other stakeholders within IDC to ensure comprehensive and efficiency lab network optimization and transition to all-inclusive procurement pricing approach that guarantees improved access to EID. There are also discussions within PEPFAR, stakeholders and manufacturers for accelerated development and use of multi-diseases testing platforms to ensure integrated diagnostics. PEPFAR continue to work with WHO to support evaluations and PQ of platforms, including Hologic to support EID. The Hologic platform is currently used only for VL.
As part of its PEPFAR funded CDC award, CRS is supporting work with national governments to assist them in streamlining their review and approval processes for use of new diagnostic technologies. Work is focused in Uganda, Zambia, Nigeria and Tanzania. CDC has awarded PEPFAR funds to CRS.
22. Incentivize commercialization of new pediatric ARV products “at risk” to accelerate introduction and scale up of new paediatric ARV product such that product is available at time of approval/tentative approval/prequalification.
28. Partner on the assisted introduction of RAL granules for neonates, starting with the MoH of Eswatini, followed by other countries beginning early 2019, donating sufficient supplies at the outset of the project and then selling at no profit in low income and sub-Saharan African countries to ensure sustainability of the initiative.
45. Contribute to the funding of the secretariat of the Global accelerator for 2 years, plus additional funding upon achievement of milestones.
21. Support catalytic procurement of all or part of initial validation batches from manufacturers such that product availability is not delayed once approval or tentative approval is achieved.
PEPFAR placed a catalytic procurement of the recently approved lopinavir/ritonavir granules at the end of December 2018.
PEPFAR is working with Global Fund and other partners on additional methods to optimize supply of pediatric lopinavir/ritonavir products this year to support the urgent effort to use LPV/r instead of nevirapine for children weighing less than 20kg. PEPFAR has already prevented use of its funds for procurement of nevirapine based treatment regimens for children and has worked closely with GF and host country governments to promote phase-out of nevirapine-based treatment for children this year. In addition, PEPFAR, in close coordination with WHO, has requested in official COP19 guidance that country programs adopt use of DTG50mg tablets beginning at body weight of 20kg in children and is working closely with country partners to ensure this recommendation is taken up.
PEPFAR and Global Fund gave Mylan and Cipla information on the expected demand for LPV/r granules and pellets (respectively), which enabled Mylan and Cipla to consider ramping up production.
PEPFAR and Global Fund have worked with Cipla and Mylan to support an increase in production capacity of LPV/r granules and pellets and we expect capacity to meet demand by FY 20, Q2.
PEPFAR’s prioritization of eliminating NVP in treatment regimens and of adopting policy to give DTG 50mg FCT to children down to 20kg is being implemented in a number of country programs and we continue to track and push remaining countries to adopt this policy.
PEPFAR also acknowledges its Vatican meeting commitment to pursue greater access of DRV 75mg and RTV 25 mg for children served in PEPFAR-supported programs.
PEPFAR is working with Janssen to make DRV 75 mg available. Through PEPFAR’s work with Janssen, DRV 75 mg will be available and orders are being placed.
PEPFAR with GAP-f is working with Cipla to accelerate the availability of RTV 25 mg.
PEPFAR has been working with Viiv and CHAI to make DTG dispersible tablets available for kids through regular meetings to track progress on study/regulatory approval and anticipatory planning to accelerate access/uptake of pediatric DTG in country programs.
PEPFAR stands ready to act on this commitment for optimal pediatric ARV products, particularly if new gaps are identified.
PEPFAR has worked closely with ViiV and CHAI to prepare countries for an accelerated introduction and scale up of pediatric DTG dispersible tablets (5 mg, 10 mg) (to be distinguished from DTG 10 mg film coated). PEPFAR COP 20 guidance states that - as new pediatric DTG dosing recommendations and pediatric DTG formulations become available - country programs should promptly make these products available, including ensuring implementing partners have work plans with clear steps for transition to DTG for younger patients when formulations become available. Countries submitted an update of their progress towards pediatric treatment optimization efforts including an update on the plan to include DTG dispersible tablets in the next iteration of the national treatment guidelines. PEPFAR will use the pediatric treatment optimization updates in order to guide plans for HQ technical assistance to the countries.
Training workshops were conducted for 60 Healthcare workers in 6 provinces on dosage calculation and caregiver education.
Having challenges with transport of RAL granules for neonates and also PIMA cartridges, there is reluctance to transport these to hospitals and clinic sites for use of these with neonates. Resolving this by working with MOH to find other transport sources. Also having challenges with multi-month dispensing for young children who need more frequent weight-based changes.
Using PEPFAR funding through a CDC award, CRS is supporting EGPAF to develop and roll out a program to introduce RAL granules for infants who test positive at birth, starting in one country in 2019, and then expanding to others. Merck produced and donated the initial batch of product for this program. Eswatini is currently focused on other priorities in its program and so we will start off in a different country that should be identified by May 2019. Zimbabwe was prepared to start this project but trainings have been delayed due to COVID-19.
MSD confirmed RAL granules and chewable tablets will be available for use by end Q2 2019.
PEPFAR has provided funding through the CDC award to CRS that will be used to support a portion of the Global Accelerator (GAPf) secretariat.